Company Description
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.
The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which is in Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
It also develops HCW9201 + HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer.
The company has a license agreement with Wugen Inc. for two molecules constructed with its TOBI platform; and a license, research and co-development agreement with WY Biotech for its preclinical molecules which were built with the TRBC platform technology.
HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Country | United States |
Founded | 2018 |
IPO Date | Jul 20, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 36 |
CEO | Hing Wong |
Contact Details
Address: 2929 North Commerce Parkway Miramar, Florida 33025 United States | |
Phone | 954 842 2024 |
Website | hcwbiologics.com |
Stock Details
Ticker Symbol | HCWB |
Exchange | NASDAQ |
Stock Type | Common Stock |
Share Class | Class A Shares |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $8.00 |
CIK Code | 0001828673 |
CUSIP Number | 40423R105 |
ISIN Number | US40423R1059 |
Employer ID | 82-5024477 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Hing C. Wong Ph.D. | Founder, Chief Executive Officer, Director and Secretary |
Rebecca Byam CPA, M.B.A. | Chief Financial Officer |
Dr. Peter Rhode Ph.D. | Chief Scientific Officer and Vice President of Clinical Operations |
Nicole Valdivieso Esq. | Vice President of Legal Affairs |
Lee D. Flowers | Senior Vice President of Business Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
Apr 28, 2025 | ARS | Filing |
Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 22, 2025 | 8-K | Current Report |
Apr 16, 2025 | EFFECT | Notice of Effectiveness |
Apr 16, 2025 | 424B3 | Prospectus |
Apr 14, 2025 | 8-K | Current Report |
Apr 7, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Apr 1, 2025 | 8-K | Current Report |
Apr 1, 2025 | 8-K | Current Report |